Mineralcorticoid receptor antagonist for producing drug for permanent treatment of endometriosis, comprises spironolactone, eplerenone and drospirenone

MOELLER CARSTEN, KAUFMANN-REICHE ULRIKE, SCHMIDT ANJA, FUHRMANN ULRIKE
2008
Other OA: closed Metadata only
⚙ AI-generated summary by qwen3.7-flash, 2026-09-19 ⓘ

This invention proposes a drug formulation for the permanent treatment of endometriosis comprising mineralcorticoid receptor antagonists such as spironolactone, eplerenone, and drospirenone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The mineralcorticoid receptor antagonist comprises spironolactone, eplerenone and drospirenone. Glucocorticoid, progesterone receptor antagonist and estrogen receptor antagonist are also included. The estrogen is ethinylestradiol. - ACTIVITY : Gynecological. - MECHANISM OF ACTION : Mineralcorticoid receptor antagonist Gonadotropin-releasing hormone (GnRH) agonist.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00